Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease ...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop ...
Find out if Maze Therapeutics Inc (MAZE:XNAS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company ...
Stay up to date on how Maze Therapeutics Inc (MAZE:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.
Maze Therapeutics is playing a long game — it doesn't expect to take a drug into a clinical trial for another two to three years — and it is vague about its initial drug targets.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
Maze Therapeutics, Inc. 競合他社・同業他社分析 - Life Sciences セクター
Our AI model demonstrates 57% historical accuracy for MAZE predictions, based on advanced machine learning algorithms trained on over 10 years of market data.